DNA Vaccine

被引：83

作者：

Cui, Zhengrong ^{[1
]}

机构：

[1] Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, Corvallis, OR 97331 USA

来源：

NON-VIRAL VECTORS FOR GENE THERAPY, SECOND EDITION: PART 2 | 2005年 / 54卷

关键词：

D O I：

10.1016/S0065-2660(05)54011-2

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The DNA vaccine has proven to be one of the most promising applications in the field of gene therapy. Due to its unique ability to readily induce humoral as well as cellular immune responses, it attracted great interest when the concept was first confirmed in the early 1990s. After thousands of articles related to the DNA vaccine were published, scientists began to realize that although the DNA vaccine is very effective in small animal models, its effectiveness in recent clinical trails is rather disappointing. Therefore, current effort has been shifted to understanding the different performance of the DNA vaccine in mouse and large animal models and on how to transfer the success of the DNA vaccine in small animals to large animals and humans. (C) 2005, Elsevier Inc.

引用

页码：257 / 289

页数：33

共 102 条

[21] Bilayer films for mucosal (genetic) immunization via the buccal route in rabbits [J].

Cui, ZR ;

Mumper, RJ .

PHARMACEUTICAL RESEARCH, 2002, 19 (07) :947-953

[22] Genetic immunization using nanoparticles engineered from microemulsion precursors [J].

Cui, ZR ;

Mumper, RJ .

PHARMACEUTICAL RESEARCH, 2002, 19 (07) :939-946

[23] DNA-MEDIATED IMMUNIZATION IN MICE INDUCES A POTENT MHC CLASS I-RESTRICTED CYTOTOXIC T-LYMPHOCYTE RESPONSE TO THE HEPATITIS-B ENVELOPE PROTEIN [J].

DAVIS, HL ;

SCHIRMBECK, R ;

REIMANN, J ;

WHALEN, RG .

HUMAN GENE THERAPY, 1995, 6 (11) :1447-1456

[24] Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine [J].

Deck, RR ;

DeWitt, CM ;

Donnelly, JJ ;

Liu, MA ;

Ulmer, JB .

VACCINE, 1997, 15 (01) :71-78

[25] Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A [J].

Epstein, JE ;

Charoenvit, Y ;

Kester, KE ;

Wang, RB ;

Newcomer, R ;

Fitzpatrick, S ;

Richie, TL ;

Tornieporth, N ;

Heppner, DG ;

Ockenhouse, C ;

Majam, V ;

Holland, C ;

Abot, E ;

Ganeshan, H ;

Berzins, M ;

Jones, T ;

Freydberg, CN ;

Ng, J ;

Norman, J ;

Carucci, DJ ;

Cohen, J ;

Hoffman, SL .

VACCINE, 2004, 22 (13-14) :1592-1603

[26] TARGETING ANTIGEN INTO THE PHAGOCYTIC PATHWAY IN-VIVO INDUCES PROTECTIVE TUMOR-IMMUNITY [J].

FALO, LD ;

KOVACSOVICSBANKOWSKI, M ;

THOMPSON, K ;

ROCK, KL .

NATURE MEDICINE, 1995, 1 (07) :649-653

[27]

Feltquate DM, 1997, J IMMUNOL, V158, P2278

[28]

FREUND J, 1951, AM J CLIN PATHOL, V21, P645

[29] DNA VACCINES - PROTECTIVE IMMUNIZATIONS BY PARENTERAL, MUCOSAL, AND GENE-GUN INOCULATIONS [J].

FYNAN, EF ;

WEBSTER, RG ;

FULLER, DH ;

HAYNES, JR ;

SANTORO, JC ;

ROBINSON, HL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (24) :11478-11482

[30] DNA vaccines: Immunology, application, and optimization [J].

Gurunathan, S ;

Klinman, DM ;

Seder, RA .

ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :927-974

← 1 2 3 4 5 6 7 8 9 10 →